Bharat Parenterals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Bharat Parenterals Limited Pharmaceutical Export Portfolio Dataset — 10 Products, $5.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bharat Parenterals Limited — Pharmaceutical Exporter Profile (2026) | 10 Products, $5.2M Trade | TransData Nexus

Bharat Parenterals Limited

Indian Pharmaceutical Exporter · Antiviral & HIV Medications Specialist · $5.2M Total Trade · DGFT Verified

Bharat Parenterals Limited is an Indian pharmaceutical exporter with a total trade value of $5.2M across 10 products in 8 therapeutic categories. Based on 209 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Dolutegravir ($1.4M), Tenofovir ($1.4M), Erythromycin ($1.4M).

Bharat Parenterals Limited — Export Portfolio & Destination Treemap

Bharat Parenterals Limited pharmaceutical export portfolio — 10 products across 8 therapeutic categories. Source: Indian Customs (DGFT).

Who is Bharat Parenterals Limited? — Company Overview & Market Position

Bharat Parenterals Limited (BPL) is a pharmaceutical company established in 1992, headquartered in Vadodara, Gujarat, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. BPL is a publicly listed entity with the Corporate Identification Number (CIN) L24231GJ1992PLC018237. As of December 2025, the company reported a workforce of 396 employees. In the fiscal year ending March 2025, BPL reported a net income of INR 82.3 million, a significant increase from INR 12.8 million in the same period the previous year. The company's official website is www.bplindia.in.

What Does Bharat Parenterals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Dolutegravir$1.4M 2Tenofovir$1.4M

Product Portfolio — Top 10 by Export Value

Bharat Parenterals Limited exports 10 pharmaceutical products across 8 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Dolutegravir	Antiviral & HIV Medications	$1.4M	28	0.0%	13
2	Tenofovir	Antiviral & HIV Medications	$1.4M	28	0.0%	11
3	Erythromycin	Antibiotics	$1.4M	37	1.7%	7
4	Acetylsalicylic	Combination Drugs	$239.6K	21	5.5%	6
5	Salicylic	Combination Drugs	$239.6K	21	1.4%	14
6	Lactulose	Gastrointestinal	$171.8K	4	1.3%	10
7	Ceftazidime	Advanced Antibiotics	$154.2K	6	1.4%	13
8	Diazepam	CNS & Psychiatric	$101.1K	11	1.3%	13
9	Aminophylline	Respiratory & OTC	$92.6K	33	1.6%	8
10	Praziquantel	Antimalarial & Antiparasitic	$74.4K	20	2.5%	7

Bharat Parenterals Limited exports 10 pharmaceutical products across 8 therapeutic categories with a total export value of $5.2M. The top category is Antiviral & HIV Medications (53.6% of portfolio), followed by Antibiotics (25.9%), indicating a concentrated portfolio with the top 5 products accounting for 88.6% of total export value.

Bharat Parenterals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

BPL operates a WHO-GMP accredited manufacturing facility located in Vadodara, Gujarat. The plant spans over 30,000 square feet and is equipped to produce a diverse range of pharmaceutical formulations, including tablets, capsules, oral liquids, eye drops, ointments, lotions, and creams. The facility is designed to handle large batch sizes, ensuring scalability and efficiency in production.

3Key Leadership

The leadership team at BPL is headed by Managing Director Mr. Bharat Kumar R. Desai, who has been with the company since its inception in 1992. Other key executives include Mr. Hemang Jayendrabhai Shah, serving as Executive Director since 2010, and Mr. Shaileshkumar Gabhawala, an Independent Non-Executive Director since 2017. The Board also includes Independent Non-Executive Directors such as Ms. Zankhana Bimalkumar Sheth and Mr. Mukeshbhai Jivrajbhai Patel.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Bharat Parenterals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

BPL has made significant strides in obtaining regulatory approvals for its products in various international markets. The company holds WHO-GMP certification for its manufacturing facility, which is a prerequisite for exporting to numerous countries. Additionally, BPL has been recognized as a 2 Star Export House, indicating its established presence in the export market. While specific details regarding approvals from the US FDA, EMA, MHRA, and TGA are not publicly disclosed, the company's adherence to WHO-GMP standards suggests a commitment to meeting international regulatory requirements.

2Emerging Markets

BPL has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification facilitates access to these regions, as it is recognized by the World Health Organization and many national regulatory authorities. BPL's diverse product portfolio, encompassing over 800 products across 20 therapeutic categories, positions it well to cater to the varied healthcare needs of these markets.

3Geographic Strategy

Bharat Parenterals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding BPL's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. The company's adherence to WHO-GMP standards and its status as a 2 Star Export House suggest a commitment to meeting international regulatory standards, which may facilitate market access in the United States. However, without explicit FDA approvals, the company's ability to market products in the U.S. remains uncertain.

2WHO & EU GMP

BPL's manufacturing facility holds WHO-GMP certification, indicating compliance with international manufacturing standards. This certification is essential for exporting pharmaceutical products to various countries and reflects the company's commitment to quality and regulatory compliance. While specific details regarding EU GMP certificates and EDQM status are not publicly disclosed, the WHO-GMP certification suggests that BPL's manufacturing practices align with international quality standards.

3CDSCO & Indian Regulatory

Bharat Parenterals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

BPL operates in a competitive pharmaceutical market, facing competition from both domestic and international companies. While specific market share data is not publicly available, the company's focus on high-demand therapeutic areas such as Antiviral & HIV Medications and Antibiotics positions it in segments with significant competition. To enhance its competitive standing, BPL may consider diversifying its product portfolio and expanding its presence in emerging markets.

2Key Differentiators

BPL's key differentiators include its WHO-GMP accredited manufacturing facility, a diverse product portfolio spanning over 800 products across 20 therapeutic categories, and a strong export presence as a 2 Star Export House. These factors collectively contribute to the company's ability to meet a wide range of healthcare needs and maintain a competitive edge in the pharmaceutical industry.

3Strategic Position

BPL's current strategic direction focuses on the manufacturing of generic pharmaceutical formulations, with an emphasis on high-demand therapeutic areas such as Antiviral & HIV Medications and Antibiotics. The company's future outlook includes expanding its product portfolio, enhancing operational efficiency, and increasing its presence in both regulated and emerging markets. By leveraging its manufacturing capabilities and regulatory certifications, BPL aims to strengthen its position in the global pharmaceutical market.

Buyer Due Diligence Brief — Evaluating Bharat Parenterals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

BPL has demonstrated a consistent track record in pharmaceutical manufacturing, with a reported export value of $5.2 million USD across 209 shipments from 2022 to 2026. The company's adherence to WHO-GMP standards and its status as a 2 Star Export House reflect its commitment to quality and reliability. However, the high concentration of exports in a few products suggests potential risks associated with over-reliance on a limited product range. Diversifying its product offerings could enhance the company's resilience and appeal to a broader customer base.

2Certifications to Verify

Importers should verify the following certifications when considering BPL as a supplier:

WHO-GMP Certification: Confirms compliance with international manufacturing standards.

ISO 9001:2015 Certification: Indicates adherence to quality management systems.

ISO 10002:2014 Certification: Demonstrates commitment to customer satisfaction and complaint handling.

Frequently Asked Questions — Bharat Parenterals Limited

How many pharmaceutical products does Bharat Parenterals Limited export from India?

Bharat Parenterals Limited exports 10 pharmaceutical products across 8 therapeutic categories. The top exports are Dolutegravir ($1.4M), Tenofovir ($1.4M), Erythromycin ($1.4M), Acetylsalicylic ($239.6K), Salicylic ($239.6K). Total export value is $5.2M.

What is Bharat Parenterals Limited's total pharmaceutical export value?

Bharat Parenterals Limited's total pharmaceutical export value is $5.2M, based on 209 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Bharat Parenterals Limited cover?

Bharat Parenterals Limited exports across 8 therapeutic categories. The largest are Antiviral & HIV Medications (53.6%, 2 products), Antibiotics (25.9%, 1 products), Combination Drugs (9.2%, 2 products).

Get Full Bharat Parenterals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.